College of Pharmacy Faculty Research ​and Publications

Impact of the OATP1B1 c.521T>C Single Nucleotide Polymorphism on the Pharmacokinetics of Exemestane in Healthy Post-Menopausal Female Volunteers

Document Type

Article

Publication Title

Journal of Clinical Pharmacy and Therapeutics

Publication Date

10-2017

Volume

42

Issue

5

First Page

547

Last Page

553

Abstract

WHAT IS KNOWN AND OBJECTIVE:

OATP1B1 mediates the transport of a diverse range of amphiphilic organic compounds that include bile acids, steroid conjugates and hormones. This retrospective pharmacogenetic study was conducted to assess the impact of the OATP1B1c.521T>C single nucleotide polymorphism (SNP) on the pharmacokinetics of the steroidal aromatase inhibitor drug exemestane in healthyvolunteers.

METHODS:

Exemestane (25 mg) was administered orally to 14 healthy post-menopausal women. All of the 14 subjects were sampled for pharmacokinetic (PK) analyses and retrospectively genotyped for OATP1B1 c.521T>C (rs 4149056).

RESULTS AND DISCUSSION:

Of the 14 subjects enrolled in the study, five were carriers of the minor C allele (OATP1B1 c.521TC+CC) and the remaining nine were carriers of the OATP1B1 c.521TT genotype. PK was assessed over 8 hours post-dosing. Our results showed statistically significant differences (P=.04) in the plasma exemestane AUC0-8 between the OATP1B1 genotype groups. Our data also showed statistically significant differences (P=.04) in the plasma AUC0-8 of 17-hydroexemestane (the major biologically active metabolite) between the OATP1B1 genotype groups.

WHAT IS NEW AND CONCLUSION:

Our data suggest that the OAPTP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans.

Copyright held by

John Wiley & Sons Ltd

Link to Full Text

Share

COinS